Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) announced that Chief Executive Officer Amir Reichman will co-lead a Manufacturers Association of Israel-organized roundtable discussion during HealthIL Week 2026. The session, titled "Biopharma Manufacturing in Israel: Capabilities, Gaps, and Scale," is scheduled for January 19, 2026, at Expo Tel Aviv.
The roundtable will focus on Israel's biopharma development and manufacturing ecosystem, including early-stage development, chemistry, manufacturing, and controls (CMC) activities, and clinical manufacturing. Discussions will also address readiness for later-stage and commercial manufacturing. This comprehensive examination of the sector's infrastructure comes at a time when global biopharmaceutical supply chains face increasing scrutiny and demand for regional capabilities grows.
The event is expected to bring together representatives from government agencies, biopharma manufacturers, contract development and manufacturing organizations (CDMOs), multinational pharmaceutical companies, biotech firms, and investors. These stakeholders will examine current capabilities, structural gaps, and collaboration models shaping the sector's future. For business and technology leaders, this gathering represents a critical assessment of Israel's positioning within the global biopharma manufacturing landscape, which has become increasingly strategic following recent global health challenges.
Scinai Immunotherapeutics operates through two complementary business units that reflect the dual focus of the roundtable discussion. Scinai Bioservices functions as a boutique CDMO providing analytical method development, process development, and clinical current good manufacturing practice (cGMP) manufacturing services for biotech clients worldwide. Meanwhile, Scinai R&D focuses on developing innovative inflammation and immunology (I&I) therapeutics based on NanoAbs, which are VHH antibody fragments with unique physicochemical properties suitable for advanced mono- and multi-specific antibody formats.
The company's latest news and updates relating to SCNI are available in its newsroom at https://ibn.fm/SCNI. The roundtable announcement was distributed through BioMedWire, a specialized communications platform focused on biotechnology, biomedical sciences, and life sciences sectors. BioMedWire is one of 75+ brands within the Dynamic Brand Portfolio at IBN that delivers various communication solutions, including access to wire distribution networks, article syndication to 5,000+ outlets, enhanced press release services, and social media distribution. More information about BioMedWire is available at https://www.BioMedWire.com.
For industry observers and business leaders, this roundtable represents more than a single corporate announcement. It signals Israel's concerted effort to assess and potentially expand its biopharmaceutical manufacturing capabilities at a time when global health security and supply chain resilience have become paramount concerns. The inclusion of government agencies alongside private sector participants suggests potential policy implications that could affect investment flows, regulatory frameworks, and international partnerships in the biopharma sector.
The timing of this discussion in early 2026 provides a forward-looking perspective on how Israel plans to address manufacturing gaps that have been exposed during recent global health emergencies. For technology leaders, the focus on advanced manufacturing capabilities and innovative therapeutic formats like NanoAbs represents the intersection of biotechnology innovation with sophisticated production technologies that could redefine treatment paradigms for complex diseases.
